452 related articles for article (PubMed ID: 21924648)
1. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine.
Wang CY; Hua R; Liu L; Zhan X; Chen S; Quan S; Chu QJ; Zhu YT
Cancer Med; 2017 Mar; 6(3):689-697. PubMed ID: 28205361
[TBL] [Abstract][Full Text] [Related]
4. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
[TBL] [Abstract][Full Text] [Related]
5. The granulocyte macrophage-colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer.
Zhu YT; Zhao Z; Fu XY; Luo Y; Lei CY; Chen W; Li F; Pang SY; Chen SS; Tan WL
Stem Cell Res; 2014 Jul; 13(1):111-22. PubMed ID: 24874290
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin-21 surface-modified MB49 cell vaccine for treatment of metastatic bladder in mice].
Peng J; Shi X; Chen D; Liang Z; Lan K; Gao J; Tan W
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(6):807-11. PubMed ID: 22699059
[TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
8. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
Guo C; Liu QG; Yang W; Yao YM
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
[TBL] [Abstract][Full Text] [Related]
9. [Application of fusion gene mGM-CSF/hIL-2 to specific immunotherapy induced by hepatic tumor cell vaccine].
Yang W; Guo C; Liu QG
Ai Zheng; 2008 Feb; 27(2):149-54. PubMed ID: 18279611
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
12. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer.
Yin W; He Q; Hu Z; Chen Z; Qifeng M; Zhichun S; Zhihui Q; Xiaoxia N; Li J; Gao J
Vaccine; 2010 Jul; 28(31):4937-44. PubMed ID: 20653081
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical anchoring of streptavidin-tagged interleukin-4 fusion protein for immunotherapy of mouse superficial bladder cancer].
Zhang Z; Xu XL; Ma L; Li JL; Hu ZM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):331-5. PubMed ID: 22883451
[TBL] [Abstract][Full Text] [Related]
15. Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine.
Zhu YT; Pang SY; Lei CY; Luo Y; Chu QJ; Tan WL
Stem Cell Res Ther; 2015 Nov; 6():224. PubMed ID: 26566931
[TBL] [Abstract][Full Text] [Related]
16. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer.
Zhang P; Wang J; Wang D; Wang H; Shan F; Chen L; Hou Y; Wang E; Lu CL
Int Immunopharmacol; 2012 Nov; 14(3):252-60. PubMed ID: 22884511
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
19. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
Toubaji A; Hill S; Terabe M; Qian J; Floyd T; Simpson RM; Berzofsky JA; Khleif SN
Vaccine; 2007 Aug; 25(31):5882-91. PubMed ID: 17602804
[TBL] [Abstract][Full Text] [Related]
20. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model.
Zhao F; Dou J; He XF; Wang J; Chu L; Hu W; Yu F; Hu K; Wu Y; Gu N
Vaccine; 2010 Apr; 28(16):2846-52. PubMed ID: 20153795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]